Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

The foundation of patient-focused drug development (PFDD) is to involve patients in the entire drug development process, from clinical trial design to post-market surveillance. While traditional ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Canaccord Genuity Capital Markets has downgraded Pliant Therapeutics (NASDAQ:PLRX) to hold from buy following news that the company has paused a clinical trial for its drug bexotegrast in the ...

Fintel reports that on February 10, 2025, JP Morgan downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...